


### Fund performance



The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter.<sup>1</sup>

### Expense ratios

Fiscal year ended March 30 (%)

Annual Expenses	Percent of Net Assets	Percent of Managed Assets
Management Fees	1.25	1.00
Other Expenses	0.17	0.14
Operating Expenses (net of fee waiver)	1.42	1.14
Leverage Costs	1.68	1.34
Total Expenses	3.28	2.62
Total Expenses before Fee Waiver	3.28	2.62

Effective upon the close of business on October 27, 2023, the Adviser entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding leverage costs, interest, taxes, brokerage commissions, acquired fund fees and expenses and any non-routine expenses) from exceeding 1.44% of the average daily net assets of the Fund on an annualized basis for twelve months (the "Expense Limitation Agreement"). The Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund's trustees who are not "interested persons" of the Fund (as defined in the 1940 Act). Leverage Costs include interest, fees, and other other up front/offering costs associated with the leverage struture for the Fund. Gross Operating Expenses include the Fee Waiver and Leverage Costs.

### Performance

The latest available performance figures have been calculated net-of-fees in U.S. dollars for the period:

Cumulative and annualized total return as of June 30, 2025 (%)

	NAV	Market price
Quarter to date	-9.50	-8.23
Year to date	-5.55	3.01
1 Year	-9.01	0.36
3 years (p.a.)	2.58	6.32
5 years (p.a.)	5.85	8.84
10 years (p.a.)	6.05	7.47

**Past Performance is no guarantee of future results.** Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be lower or higher than the performance quoted. NAV return data includes investment management fees, custodial charges and administrative fees (such as Director and legal fees) and assumes the reinvestment of all distributions. abrdn Inc. (the "Adviser") became the Fund's adviser on October 27, 2023. For periods prior to that date, the returns reflect performance information from a prior, unaffiliated adviser. The Fund is subject to investment risk, including the possible loss of principal. Returns for periods less than one year are not annualized.

<sup>1</sup> The Fund's blended benchmark comprises 80% S&P Composite 1500 Healthcare Index, 15% S&P 500 HealthCare Corporate Bond Index and 5% S&P Composite 1500 Health Care REITs Index.

The S&P Composite 1500 Healthcare Index includes securities of those companies listed on the S&P Composite 1500 Index classified according to the Industry Classification Benchmark as healthcare. The S&P Composite 1500 Index is a broad market portfolio representing the large-, mid- and small-cap segments of the U.S. equity market.

The S&P 500 Healthcare Corporate Bond Index includes securities of those companies listed on the S&P 500 Bond Index classified according to the Industry Classification Benchmark as healthcare. The S&P 500 Bond Index is an unmanaged index that comprises the corporate debt of those companies listed on the S&P 500 Index, which is considered representative of the U.S. stock market.

The S&P Composite 1500 Healthcare REITs Index includes securities of those companies listed on the S&P Composite 1500 Index classified according to the Industry Classification Benchmark as healthcare REITs.

Indexes are unmanaged and have been provided for comparison purposes only. No fees or expenses are reflected. You cannot invest directly in an index.

For current holdings information, please visit [abrdn Healthcare Opportunities Fund - Portfolio Holdings](#)



Among the detractors, UnitedHealth Group shares fell sharply after the company unexpectedly lowered earnings guidance because of higher medical costs and increased regulatory scrutiny over Medicare billing practices. Sarepta Therapeutics shares fell sharply after a second patient death associated with Elevidys gene therapy prompted increased scrutiny from the Food and Drug Administration and the suspension of dosing activities. Thermo Fisher Scientific lowered its profit forecasts amid cautious biopharmaceutical and government research funding environments, with tariff-related issues also affecting its global business.

In terms of positive contributors, ARS Pharmaceuticals experienced significant share price appreciation after positive clinical data and rapid regulatory progress for its novel nasally delivered epinephrine product, which offers a potentially transformative, user-friendly alternative to current injectable treatments for severe allergic reactions. Intuitive Surgical maintained strong financial performance with sustained revenue growth, supported by global adoption and increased utilisation of its robotic surgical systems. Tenet Healthcare Corporation notably improved operational efficiency and patient volume growth, which substantially enhanced quarterly financial performance.

## Activity

We initiated a position in Myriad Genetics, a mid-cap diagnostics company, after a period of share-price underperformance. The decision reflected a turnaround in the genetic testing sector, supported by the launch of new cancer and women's health tests, as well as ongoing improvements in the company's fundamentals and cost restructuring.

We added Repligen, a life science tools provider specialising in bioprocessing equipment for drug manufacturers, as a new holding after a pullback in its share price. The decision reflected the company's exposure to recovering biotechnology research and development activity.

We initiated a position in Krystal Biotech, a newly commercial-stage gene therapy company. The firm received approval for its lead dermatology gene therapy in the prior year and has since demonstrated ongoing commercial momentum as that product launch accelerated. Krystal Biotech also has a broad pipeline of genetic lung and skin disease candidates.

Meanwhile, we sold our holding in Biogen after the stock appreciated following approval of its Alzheimer's drug.

We also disposed of our holding in Illumina amid ongoing regulatory and competitive pressures. The company faces continued headwinds after its acquisition of GRAIL, as well as increased competition in the deoxyribonucleic acid sequencing market.

Lastly, we sold our holding in IDEXX Laboratories after a period of strong share-price performance.

## Market review

US equities ended the quarter notably higher. Investor sentiment was initially weighed down in April by President Trump's sweeping tariff policies. Although a 90-day pause was later announced for most of these tariffs, China remained subject to US duties of over 100%. However, equities recovered somewhat towards the end of April on hopes of a de-escalation in tensions. In May, the US and China agreed at talks in Geneva to implement substantial reciprocal tariff reductions for 90 days. This temporary agreement was reaffirmed at the US-China trade talks in London in June. Investors' focus then shifted to rising tensions in the Middle East after Israel launched strikes against Iran in response to its nuclear programme, with the US then carrying out large-scale airstrikes on Iranian nuclear facilities. However, a US-brokered ceasefire between Israel and Iran eased tensions somewhat.

The performance of the US healthcare sector lagged that of US equities over the quarter. Cyclical sectors fared relatively well as easing US-China trade tensions led to reduced economic and geopolitical uncertainty. These sectors included information technology, communication services, industrials and consumer discretionary. Meanwhile, apart from healthcare, other defensive sectors, including consumer staples, real estate and utilities, also underperformed as investors became less risk averse as global trade tensions eased. In addition, healthcare stocks faced headwinds from regulatory uncertainty, including proposed Medicaid work requirements and uncertainty in biotechnology regulation and funding. Energy was another laggard as oil prices spent much of the quarter in decline before rebounding towards the end of the period due to Middle East tensions to finish only slightly lower.

## Outlook & strategy

Uncertainty continues to cloud the macroeconomic, geopolitical and market outlook. A combination of shifting fiscal and monetary policies along with structural changes in global trade dynamics has created an increasingly volatile market environment. Much of the focus remains on the Trump administration's tariff strategy and its potential implications for economic growth and inflation. However, the broader macroeconomic backdrop is further complicated by proposed tax cuts, widening budget deficits, evolving interest-rate policy, healthcare reform and a range of other policy initiatives that may have both intended and unintended consequences. Given the rapidly evolving landscape, market participants are struggling to build meaningful conviction around the trajectory of both domestic and international economies.

In general, the near- and long-term outlooks for healthcare companies remain favourable. Long-term demographic trends of an aging population should continue to support the growing demand for new healthcare products and therapies. Due to the healthcare sector's generally defensive characteristics, its relative underperformance in the short term should position it favourably, especially if the US and global economies slow down.

## Important Information

International investing entails special risk considerations, including currency fluctuations, lower liquidity, economic and political risks, and differences in accounting methods; these risks are generally heightened for emerging market investments.

Investments in THQ may be subject to additional risks including limited operating history, security selection, concentration in the healthcare industries, pharmaceuticals sector, biotechnology industry, managed care sector, life science and tool industry, healthcare technology sector, healthcare services sector, healthcare supplies sector, healthcare facilities sector, healthcare equipment sector, healthcare distributors sector, healthcare REIT, interest rate, credit/default, non-investment grade securities, key personnel, discount to NAV, anti-takeover provisions, related party transactions, non-diversification, government intervention, market disruption, geopolitical, and potential conflicts of interest. Please see the Fund's most recent annual report for more information on risks applicable to the Fund. As of 9/30/2023, Tekla Capital Management LLC was the Fund's investment manager. Effective immediately after the market close on 10/27/2023, abrdn Inc. became the Fund's investment manager. Destra Capital Advisors LLC, a registered investment advisor, is providing secondary market servicing for the Fund.

Please see the Fund's most recent annual report for more information on risks applicable to the Fund.

Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the Fund. The net asset value (NAV) is the value of an entity's assets less the value of its liabilities. The market price is the current price at which an asset can be bought or sold. There is no assurance that the Fund will achieve its investment objective. Past performance does not guarantee future results.

This commentary is for informational purposes only, and is not intended as an offer or recommendation with respect to the purchase or sale of any security, option, future or other derivatives in such securities.

The information contained herein is current at the time of distribution, intended to be of general interest only and does not constitute legal or tax advice. Aberdeen does not warrant the accuracy, adequacy or completeness of the information and materials contained in this document and expressly disclaims liability for errors or omissions in such information and materials. Aberdeen reserves the right to make changes and corrections to its opinions expressed in this document at any time, without notice.

Some of the information in this document may contain projections or other forward-looking statements regarding future events or future financial performance of countries, markets or companies. These statements are only predictions and actual events or results may differ materially. The reader must make his/her own assessment of the relevance, accuracy and adequacy of the information contained in this document, and make such independent investigations as he/she may consider necessary or appropriate for the purpose of such assessment.

Any opinion or estimate contained in this document is made on a general basis and is not to be relied on by the reader as advice. Neither Aberdeen nor any of its agents have given any consideration to nor have they made any investigation of the investment objectives, financial situation or particular need of the reader, any specific person or group of persons. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the reader, any person or group of persons acting on any information, opinion or estimate contained in this document.

Aberdeen Investments Global is the trade name of Aberdeen's investments business, herein referred to as "Aberdeen Investments" or "Aberdeen". In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.

©2025 This material is owned by Aberdeen or one of its affiliates. This material is the property of Aberdeen and the content cannot be reproduced or used in any way without our authorization.

For more information visit [aberdeeninvestments.com](https://aberdeeninvestments.com)

Ref. AA-180725-196286-6